Form 4: Gossamer Bio Director Russell J. Cox Granted 115,000 Stock Options

Gossamer Bio, Inc. Director Russell J. Cox was granted 115,000 stock options with an exercise price of $1.36 as part of the company's Non-Employee Director Compensation Program.

Summary

• Russell J. Cox, a Director of Gossamer Bio, Inc. (GOSS), was granted 115,000 stock options on June 25, 2025.
• The stock options have an exercise price of $1.36 per share.
• The options are scheduled to expire on June 24, 2035.
• This award was made pursuant to the company's Non-Employee Director Compensation Program.
• The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to Mr. Cox's continued service on the board.
• Following this transaction, Mr. Cox directly beneficially owns 115,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options is a standard compensation practice that aligns director interests with shareholders, but it's a routine filing with no direct impact on company operations or financial results.

Positives

• The grant of stock options aligns the director's interests with shareholder value, as the options gain value if the stock price increases above the exercise price.
• The award is part of a standard Non-Employee Director Compensation Program, indicating a structured and transparent approach to director incentives.

Risks

• The value of the stock options is contingent on the future performance of Gossamer Bio's common stock; if the stock price does not exceed the exercise price of $1.36, the options may expire worthless.
• Vesting of the options is subject to the director's continued service on the board of directors, meaning the full benefit is not guaranteed if service ceases prematurely.

Future Outlook

The stock options are designed to incentivize the director by aligning their financial interests with the long-term performance of Gossamer Bio's stock, with vesting contingent on continued service.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a non-employee director, a common practice across the biotechnology and pharmaceutical industries to attract and retain qualified board members and align their interests with shareholders.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice in the biotechnology sector, similar to companies like Amgen Inc. or Gilead Sciences, Inc., which commonly use equity to incentivize long-term commitment and performance.
• The vesting schedule, tied to continued service and annual meetings, is typical for director equity awards, ensuring ongoing engagement with corporate governance.
• The exercise price being set at a specific value ($1.36) is standard for option grants, often reflecting the stock price at the time of grant, though the document does not explicitly state it's the market price.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholders by incentivizing long-term stock price appreciation. Potential dilution from option exercise is a common consideration.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest on the first anniversary of the grant date (June 25, 2025) or the next annual meeting of stockholders, whichever occurs first, subject to continued service.
• The director may choose to exercise these options at any time after vesting and before the expiration date of June 24, 2035.

Key Dates

Keywords

Gossamer Bio, GOSS, SEC Form 4, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Russell J. Cox